Zion Pharma Announces Global Agreement with Roche to Develop and Commercialize a Blood Brain Barrier Penetrant Oral HER2 Tyrosine Kinase Inhibitor
9.5.2023 09:00:00 EEST | Business Wire | Press release
Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, today announced that Roche has acquired the global rights to Zion’s lead program, ZN-A-1041. ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2). ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer. Up to 50% of patients with HER2-positive metastatic breast cancer will develop brain metastasis during the course of the disease.
"Our agreement with Roche is the culmination of a tremendous team effort to deliver a potentially best-in-class therapy for patients with HER2-positive breast cancer, particularly in the field of brain metastasis by virtue of the high blood-brain barrier permeability of this asset,” stated Zack Cheng, M.D., Ph.D., Chairman, CEO and Co-Founder of Zion Pharma Limited. “Within five years, we have gone from company formation to first-in-human, to finding a partner in Roche, who has the resources and expertise to bring ZN-A-1041 to patients with few other therapeutic options,” Dr. Cheng continued.
Dr. Ding Zhou, Ph.D., CSO and Co-Founder of Zion Pharma Limited added, “We are pleased that Roche recognizes the potential of our asset for advancing the standard of care with regards to brain penetrable compounds in HER2-positive breast cancer.”
“We are excited to enter this partnership with Zion to further develop this innovative treatment option for people with HER2-positive breast cancer. This partnership builds on Roche’s legacy and expertise in the treatment of HER2-positive breast cancer and supports our pursuit of advancing science by combining external innovation with our in-house capabilities to address areas of high unmet patient needs,” said James Sabry, Global Head of Pharma Partnering.
After a transition period, Roche will be responsible for the further development, manufacturing, and commercialization of ZN-A-1041 globally. Zion will receive up to $70 million USD in upfront and near-term milestone payments pending achievement of certain milestone events. Zion will also be eligible for up to $610 million USD in additional payments following achievement of certain development, regulatory, and sales-based milestone events by ZN-A-1041, as well as tiered royalties on sales.
About ZN-A-1041
ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2). ZN-A-1041 was designed to be blood-brain-barrier-penetrant. The ongoing Phase 1 trial is being conducted at multiple sites in the U.S. and China. Additional details will be presented at the poster sessions during the American Society of Clinical Oncology Annual Meeting in June 2023.
About Zion Pharma Limited
Zion Pharma is a private, clinical stage biotech company focused on the development of novel, small molecule, anti-tumoral agents. Founded in 2018, the company’s research headquarters are in Suzhou with additional research operations in Shanghai. The company is applying an innovative drug discovery approach, capitalizing on its DMPK expertise, to develop a pipeline of proprietary first-in-class/best-in-class compounds focused on therapeutic targets which drive tumor inhibition, including ataxia telangiectasia mutated (ATM), Kirsten RAt Sarcoma (KRAS G12D) and SMARCA2 (BRM). Additional information about Zion Pharma is available at www.zionpharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005468/en/
Contact information
For media and partnership inquiries:
J. Michael French
SVP, Corporate Development
michael.french@zionpharma.com
+1.703.338.1972
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Klarna Expands Partnership With Mollie, Bringing Enhanced Dispute Management and Consumer FX to Merchants Across Europe3.11.2026 11:00:00 EET | Press release
Klarna, the everyday finance network, announced today an expanded agreement with Mollie, one of Europe’s leading payment service providers. Building on their existing partnership, the new contract brings additional Klarna capabilities, including enhanced dispute management and consumer FX, to Mollie’s more than 350,000 merchants. The new features will roll out across all Mollie’s integrations, via direct API, hosted payment page and via their extensive Platform partner plug in ecosystem. Merchants already offering Klarna through Mollie will gain access to these features through their existing integration. Merchants new to Klarna can offer Pay in Full, Pay in 3 interest-free installments and Financing at checkout, and can enable it within minutes. With Mollie’s recent acquisition of GoCardless and coverage across all EEA markets, the expanded agreement extends Klarna’s reach and product offering across the region. “This deepened agreement with Mollie opens up Klarna to merchants across
Bizzmine Unveils More Than 40 Quality, EHS and Compliance Solutions Alongside Major Advances in AI and User Experience3.11.2026 10:47:00 EET | Press release
Bizzmine has announced a major expansion of its intelligent QHSE platform at Digital Summit 2026. The company presented more than 40 ready to use solutions spanning Quality, Environment, Health and Safety (EHS) and Compliance, together with advances in artificial intelligence and a fundamentally renewed user experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102147396/en/ Bizzmine summit panel discussion The latest developments give organisations a broader range of operational processes to manage in one environment, with connected information, common governance and a clear view of responsibilities and completed work across locations. “What impresses me most is how quickly we can now turn innovation into value for our customers,” said Mark Abbas, CEO of Bizzmine. “In just one year, we have expanded from around 15 solutions to more than 40, got recognized by leading industry analysts for our EHS capabilities, introd
Hightouch Launches Match Booster in Europe, Raising Match Rates Without Compromising Compliance3.11.2026 10:02:00 EET | Press release
Hightouch, the leading agentic marketing platform, today launched Match Booster in the UK, Germany, France, Spain, and Italy. Match Booster helps brands, agencies, media networks, and publishers reach more of their customers on more than 50 ad platforms, including Google, Meta, Amazon, TikTok, and The Trade Desk, by adding to their consented first-party data instead of replacing it. Until now, European advertisers have had two options. They could send first-party data to ad platforms alone and accept the match rates they got. Or they could hand it to a traditional onboarding provider that swaps it for a proprietary ID and drops any customer its graph can’t find, sometimes leaving audiences smaller than they started. Global companies also end up running separate US and EU workflows to meet data residency rules. “Better match rates shouldn’t depend on where your customers live,” said Matthew Lubeck, General Manager, EMEA at Hightouch. “European companies have been told that more reach me
Building on Netherlands NextGen Momentum, Trilliant Showcases Why the Next Generation of AMI is Being Defined by Choice at Enlit Europe 20263.11.2026 10:00:00 EET | Press release
Trilliant, a technology platform partner enabling utilities to gain real-time visibility and optimize performance across an increasingly dynamic energy landscape, will showcase its Power of Choice approach at Enlit Europe 2026, taking place 10–12 November in Vienna, Austria. The company will highlight how intelligent software and device-independent technologies help utilities modernize infrastructure and prepare for evolving grid demands. Trilliant’s participation at Enlit Europe follows its recent selection by Dutch distribution system operators to support the Netherlands’ NextGen smart metering programme. Trilliant’s role includes developing and delivering gateways supported by its transformed UnitySuite® platform, which will be demonstrated during the conference. At Enlit Europe, Trilliant will spotlight its Power of Choice approach, enabling utilities to integrate multiple vendors and technologies without proprietary lock-in while building a foundation for next-generation AMI and g
Cambridge International AS & A Level June Series Results to Be Released Earlier From 20273.11.2026 09:05:00 EET | Press release
Students taking Cambridge International AS & A Levels will receive their June series exam results almost two weeks earlier from 2027. Results for the June 2027 series will be released on 28 July 2027, the International Education group at Cambridge University Press & Assessment (Cambridge) announced today. The change responds to feedback from schools, students and families that earlier results would make a practical difference. Earlier results give students more time to confirm university places, complete enrolment, apply for visas and arrange travel. Bringing the date forward will allow students to take up a university place in the same calendar year in some countries, where previously they could not. Earlier results will also give universities more time to review applications, confirm offers and resolve queries, and give them greater certainty when planning their international intake. University admissions processes and academic calendars vary between countries, so the benefits of an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom